Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Escalation in demand for self-injection devices
3.2.1.2 Increase in the number of chronic diseases
3.2.1.3 Innovative technological progress
3.2.1.4 Development of the biologics market
3.2.2 Industry pitfalls & challenges
3.2.2.1 Needlestick injuries and infections
3.2.2.2 Preference over other drug delivery systems
3.2.2.3 Sterility of injectables
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.6.1 Core technologies
3.6.2 Adjacent technologies
3.7 Pricing analysis, 2023
3.7.1 By region
3.7.2 By key player
3.8 Future market trends
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Devices, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Conventional injection devices
5.2.1 Fillable syringes
5.2.2 Prefilled syringes
5.3 Self-injection devices
5.4 Needle-free injectors
5.4.1 Jet-based needle-free injectors
5.4.2 Spring-based needle-free injectors
5.4.3 Laser-powered needle-free injectors
5.4.4 Vibration-based needle-free injectors
5.5 Autoinjectors
5.5.1 Automated autoinjectors
5.5.2 Manual autoinjectors
5.6 Pen injectors
5.6.1 Single-chambered pen injectors
5.6.2 Dual-chambered pen injectors
5.7 Wearable injectors
5.8 Other devices
Chapter 6 Market Estimates and Forecast, By Formulation, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Conventional drug delivery formulations
6.2.1 Solutions
6.2.2 Reconstituted/lyophilized formulations
6.2.3 Suspensions
6.2.4 Emulsions
6.3 Novel drug delivery formulations
6.3.1 Colloidal dispersions
6.3.2 Niosomes
6.3.3 Liposomes
6.3.4 Polymeric/mixed micelles
6.3.5 Nanoparticles
6.3.6 Solid-lipid nanoparticles
6.3.7 Nanosuspensions
6.3.8 Nanoemulsions
6.4 Microparticles
6.4.1 Microspheres
6.4.2 Microcapsules
6.5 Long-acting injection formulations
Chapter 7 Market Estimates and Forecast, By Formulation Packing, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Ampoules
7.3 Vials
7.4 Cartridges
7.5 Bottles
Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Autoimmune diseases
8.2.1 Rheumatoid arthritis
8.2.2 Multiple sclerosis
8.2.3 Crohn's disease
8.2.4 Psoriasis
8.2.5 Other autoimmune diseases
8.3 Hormonal disorders
8.3.1 Diabetes
8.3.2 Anemia
8.3.3 Reproductive health disease
8.3.4 Antithrombotic/thrombolytic therapy
8.3.5 Osteoporosis
8.3.6 Growth hormone deficiency
8.4 Orphan diseases
8.5 Cancer
8.6 Infectious diseases
8.7 Other applications
Chapter 9 Market Estimates and Forecast, By Site of Administration, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Skin
9.3 Circulatory/musculoskeletal system
9.4 Organs
9.5 Central nervous system
Chapter 10 Market Estimates and Forecast, By Usage Pattern, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Curative care
10.3 Immunization
10.4 Other usage patterns
Chapter 11 Market Estimates and Forecast, By Usability, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 Disposable
11.3 Reusable
Chapter 12 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
12.1 Key trends
12.2 Hospitals and clinics
12.3 Ambulatory surgical centers
12.4 Home care settings
12.5 Other end-users
Chapter 13 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
13.1 Key trends
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 France
13.3.4 Spain
13.3.5 Italy
13.3.6 Netherlands
13.3.7 Rest of Europe
13.4 Asia Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Rest of Asia Pacific
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Argentina
13.5.4 Rest of Latin America
13.6 Middle East and Africa
13.6.1 South Africa
13.6.2 Saudi Arabia
13.6.3 UAE
13.6.4 Rest of Middle East and Africa
Chapter 14 Company Profiles
14.1 A. Menarini Diagnostics s.r.l
14.2 Abbott Laboratories
14.3 ARKRAY, Inc.
14.4 Becton, Dickinson and Company
14.5 Bio-Rad Laboratories, Inc.
14.6 Ceragem Medisys Inc.
14.7 Danaher Corporation
14.8 EKF Diagnostics
14.9 Eli Lilly and Company
14.10 F. Hoffmann-La Roche Ltd.
14.11 Pfizer Inc.
14.12 PTS Diagnostics
14.13 SAKAE HOLDINGS LTD.
14.14 Sanofi
14.15 SEKISUI CHEMICAL CO., LTD.
14.16 Siemens Healthineers AG
14.17 Trinity Biotech plc
